Navigation Links
Antigen Discovery, Inc. Awarded Grant for Chlamydia Vaccine Development
Date:9/21/2009

IRVINE, Calif., Sept. 21 /PRNewswire/ -- Antigen Discovery, Inc. ("ADi", formerly ImmPORT Therapeutics, Inc.), a leading biotech company in high throughput antigen and biomarker discovery, announced today that the Company was awarded a Phase II STTR from the National Institute of Allergy and Infectious Diseases (NIAID) under the American Recovery and Reinvestment Act (ARRA) of 2009. The $1.8 million grant will fund efforts to further test and validate novel candidate antigens discovered during the Company's successful STTR Phase I program. ADi intends to develop the novel antigens as core protective components in a vaccine against Chlamydia. ADi will collaborate with investigators in the Department of Pathology & Laboratory Medicine of School of Medicine at the University of California, Irvine (UCI).

"ADi's high throughput proteomics technology is a powerful platform to translate readily available genomic information into the development of next generation diagnostics, therapeutics and vaccines," said Dr. Xiaowu Liang, CEO of ADi. "Chlamydia trachomatis is the most common sexually transmitted bacterial pathogen. An efficacious vaccine against Chlamydia will have a tremendous health and economic impact throughout the world. We are pleased to collaborate with the leading Chlamydia researcher at UCI in applying our proven platform technology to address this critical public health concern. We are also thankful and appreciative of continued support of the US Government and NIAID on this important endeavor."

"ADi's high throughput proteomics approach has allowed us, for the first time, to successfully scan the entire proteome of Chlamydia trachomatis," added Dr. Luis de la Maza, the Principal Investigator on the STTR grant. "Our goal for this phase of the project is to identify a small subset of recombinant chlamydial antigens that induce strong protection against infection challenge. These antigens will be ideal candidates to develop a novel Chlamydia vaccine."

The two year, $1.8 million, Phase II STTR grant supplements a previously awarded Phase I STTR to ADi in 2007.

About Antigen Discovery, Inc.

Antigen Discovery, Inc. (formerly ImmPORT Therapeutics, Inc.) is a privately held biotech company with innovative technologies that offer unprecedented advantages for the rapid development of vaccines, therapeutics, and diagnostic products. The Company's high throughput proteome microarray chip fabrication and screening platform provides an order of magnitude of improvement over current antigen and biomarker discovery technologies. The Company is also working on applying their platform to the identification of markers for autoimmune disease and cancer.

    Contact

    Antigen Discovery, Inc.
    Keith B. Hoffman, Ph.D., Head of Business Development
    (949) 679-4068
    khoffman@antigendiscovery.com
    www.antigendiscovery.com


'/>"/>
SOURCE Antigen Discovery, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ImmunoVaccine Technologies Licenses Immunotopes Breast, Ovarian and Prostate Cancer Antigens
2. Medicago succesfully expresses VLP antigen for A H1N1 strain
3. Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7
4. PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
5. Antigen Discovery Inc. Awarded a SBIR Phase II Grant to Commercialize Novel Antigens for Serodiagnostic Products and Vaccine Development
6. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
7. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
8. SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY, DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS
9. ARCA Discovery, Inc. to Present at 26th Annual JPMorgan Healthcare Conference on January 8, 2008
10. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
11. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... Virgin Islands (PRWEB) , ... April 27, 2016 ... ... Company Ltd. (d/b/a Biohaven) is pleased to announce the appointment of John Tilton as ... was an Executive Director and one of the founding commercial leaders responsible for ...
(Date:4/27/2016)... (PRWEB) , ... April 27, 2016 , ... Global ... mutual endorsement of an Asia-Pacific Symposium as other research and development initiatives for potential ... Santiago officials and top Global Stem Cells Group executives began meeting to establish a ...
(Date:4/26/2016)... , ... April 26, 2016 , ... The European ... been selected as one of three finalists for the European Inventor Award 2016 in ... innovation prize will be announced at a ceremony in Lisbon on June 9th. , ...
(Date:4/26/2016)... ... April 26, 2016 , ... Seattle ... significant operating grant from 1Plus12 Corporation. The grant will be used to further ... outlined on the organization's website http://www.ivsci.org , In accounting the grant ...
Breaking Biology Technology:
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
Breaking Biology News(10 mins):